MEDP vs. TMO: Medpace vs. Thermo Fisher Scientific Stock Comparison
How do Medpace (MEDP) and Thermo Fisher Scientific (TMO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Medpace (MEDP) and Thermo Fisher Scientific (TMO) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | MEDP | TMO |
|---|---|---|
| Name | Medpace Holdings, Inc. | Thermo Fisher Scientific Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 18.27 billion USD | 257.42 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | August 11, 2016 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | MEDP | TMO |
|---|---|---|
| Total Return (1Y) | 13.29% | 24.62% |
| Total Return (3Y, Annualized) | 35.26% | 17.34% |
| Total Return (5Y, Annualized) | 24.49% | 3.11% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | MEDP | TMO |
|---|---|---|
| Volatility (1Y, Annualized) | 44.16% | 29.96% |
| Beta (5Y) | 1.10 | 0.83 |
| Max Drawdown (5Y) | -42.87% | -40.95% |
| Avg. Volume (3M) | 258.39K | 2.10M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | MEDP | TMO |
|---|---|---|
| Sharpe Ratio (1Y) | 0.20 | 0.68 |
| Sortino Ratio (1Y) | 0.26 | 1.02 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Medpace (MEDP) at 117.88% is the standout with ROE above its industry range; Thermo Fisher Scientific (TMO) at 13.38% also sits in the top quartile.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
117.88%
- MEDP
- 117.88%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.38%
- Max
- 109.18%
- TMO
- 13.38%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Medpace (MEDP) at 18.24% keeps the most of each sales dollar — above its industry’s net margin range — and Thermo Fisher Scientific (TMO) at 14.94% also retains a top-quartile share.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.24%
- MEDP
- 18.24%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.94%
- Max
- 18.05%
- TMO
- 14.94%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Medpace (MEDP) at 23.12% and Thermo Fisher Scientific (TMO) at 20.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.12%
- Max
- 83.12%
- MEDP
- 23.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.19%
- Max
- 83.12%
- TMO
- 20.19%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | MEDP | TMO |
|---|---|---|
| ROE (TTM) | 117.88% | 13.38% |
| ROA (TTM) | 18.71% | 5.19% |
| Net Margin (TTM) | 18.24% | 14.94% |
| Operating Margin (TTM) | 23.12% | 20.19% |
| Gross Margin (TTM) | 72.24% | 41.26% |
Growth
Revenue Growth
Both Medpace (MEDP) at 19.97% and Thermo Fisher Scientific (TMO) at 3.91% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Medpace (MEDP) at 20.98% and Thermo Fisher Scientific (TMO) at 7.32% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | MEDP | TMO |
|---|---|---|
| Revenue Growth (YoY) | 19.97% | 3.91% |
| Revenue Growth (3Y CAGR) | 20.12% | -0.27% |
| EPS Growth (YoY) | 20.98% | 7.32% |
| EPS Growth (3Y CAGR) | 28.04% | 0.21% |
Financial Strength
Current Ratio (MRQ)
Both Medpace (MEDP) at 0.83 and Thermo Fisher Scientific (TMO) at 1.81 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MEDP
- 0.83
- Min
- 0.10
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.81
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- TMO
- 1.81
- Min
- 0.10
Debt / Equity (MRQ)
Medpace (MEDP) at 0.29 carries an industry-typical debt-to-equity mix, while Thermo Fisher Scientific (TMO) at 0.75 uses more debt funding than most peers.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.29
- Max
- 1.42
- Q3
- 0.65
- MEDP
- 0.29
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.75
- Max
- 1.42
- TMO
- 0.75
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | MEDP | TMO |
|---|---|---|
| Current Ratio (MRQ) | 0.83 | 1.81 |
| Debt / Equity (MRQ) | 0.29 | 0.75 |
| Net Debt / EBITDA | -0.84 | 2.91 |
Dividends
Dividend Yield (TTM)
Medpace (MEDP) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a yield of 0.27%, ranking against industry peers normally.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MEDP
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.27%
- TMO
- 0.27%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Medpace (MEDP) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a payout of 9.70%, ranking against industry peers normally.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MEDP
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.70%
- TMO
- 9.70%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | MEDP | TMO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.27% |
| Dividend Payout Ratio (TTM) | 0.00% | 9.70% |
Valuation
P/E Ratio (TTM)
Both Medpace (MEDP) at 36.26 and Thermo Fisher Scientific (TMO) at 36.64 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.26
- Max
- 85.34
- Q3
- 43.46
- MEDP
- 36.26
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.64
- Max
- 85.34
- Q3
- 43.46
- TMO
- 36.64
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Medpace (MEDP) at 6.44 and Thermo Fisher Scientific (TMO) at 5.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.44
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- MEDP
- 6.44
- Q1
- 3.01
- Min
- 0.01
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.44
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- TMO
- 5.44
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Thermo Fisher Scientific (TMO) at 4.70 sits near its industry’s typical P/B ratio, while Medpace (MEDP) at 31.23 prices above its benchmark range — MEDP looks rich relative to book.
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.23
- MEDP
- 31.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70
- Max
- 13.53
- Q3
- 6.54
- TMO
- 4.70
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | MEDP | TMO |
|---|---|---|
| P/E Ratio (TTM) | 36.26 | 36.64 |
| P/S Ratio (TTM) | 6.44 | 5.44 |
| P/B Ratio (MRQ) | 31.23 | 4.70 |
| Free Cash Flow Yield (TTM) | 2.72% | 2.50% |